FDA continues to monitor contraceptive drospirenone for clot risk

09/26/2011 | Reuters · Wall Street Journal, The

The FDA remains wary of a possible risk of blood clot in women taking drospirenone-based birth control pills, such as Bayer's Yasmin and Yaz. Preliminary data from an agency-funded study show a 1.5-fold risk increase for drospirenone compared with other hormonal contraceptives. A panel of medical experts will convene Dec. 8 to tackle the issue.

View Full Article in:

Reuters · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care